Tirucherai Giridhar S, Mitra Ashim K
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Road, Kansas City, MO 64110, USA.
AAPS PharmSciTech. 2003;4(3):E45. doi: 10.1208/pt040345.
The purpose of the study was to investigate the effect of hydroxypropyl beta cyclodextrin (HPbetaCD) on aqueous solubility, stability, and in vitro corneal permeation of acyl ester prodrugs of ganciclovir (GCV). Aqueous solubility and stability of acyl ester prodrugs of Ganciclovir (GCV) were evaluated in pH 7.4 isotonic phosphate buffer solution (IPBS) in the presence and absence of HPbetaCD. Butyryl cholinesterase-mediated enzymatic hydrolysis of the GCV prodrugs was studied using various percentage w/v HPbetaCD. In vitro corneal permeation of GCV and its prodrugs (with and without 5% HPbetaCD) across isolated rabbit cornea was studied using side-by-side diffusion cells. HPbetaCD-prodrug complexation was of the A(L) type with values for complexation constants ranging between 12 and 108 M(-1). Considerable improvement in chemical and enzymatic stability of the GCV prodrugs was observed in the presence of HPbetaCD. The stabilizing effect of HPbetaCD was found to depend on the degree of complexation and the degradation rate of prodrug within the complex. Five percent w/v HPbetaCD was found to enhance the corneal permeation of only the most lipophilic prodrug GCV dibutyrate (2.5-fold compared with 0% HPbetaCD). All other prodrugs showed little or no difference in transport in the presence of 5% w/v HPbetaCD. Agitation in the donor chamber largely influenced the transport kinetics of GCV dibutyrate across cornea. Results indicate the presence of an unstirred aqueous diffusion layer at the corneal surface that restricts the transport of the highly lipophilic GCV dibutyrate prodrug. HPbetaCD improves corneal permeation by solubilizing the hydrophobic prodrug and delivering it across the mucin layer at the corneal surface.
本研究的目的是考察羟丙基-β-环糊精(HPβCD)对更昔洛韦(GCV)酰基酯前药的水溶性、稳定性及体外角膜渗透的影响。在有和没有HPβCD存在的情况下,于pH 7.4等渗磷酸盐缓冲溶液(IPBS)中评估了更昔洛韦(GCV)酰基酯前药的水溶性和稳定性。使用不同重量/体积百分比的HPβCD研究了丁酰胆碱酯酶介导的GCV前药的酶促水解。使用并排扩散池研究了GCV及其前药(有和没有5% HPβCD)在离体兔角膜上的体外角膜渗透。HPβCD-前药络合为A(L)型,络合常数的值在12至108 M⁻¹之间。在HPβCD存在下,观察到GCV前药的化学和酶稳定性有显著改善。发现HPβCD的稳定作用取决于络合程度和前药在络合物中的降解速率。发现5%重量/体积的HPβCD仅能增强最具亲脂性的前药更昔洛韦二丁酸酯的角膜渗透(与0% HPβCD相比提高了2.5倍)。在5%重量/体积的HPβCD存在下,所有其他前药在转运方面几乎没有差异或没有差异。供体室中的搅拌在很大程度上影响了更昔洛韦二丁酸酯跨角膜的转运动力学。结果表明在角膜表面存在一个未搅拌的水扩散层,该层限制了高亲脂性的更昔洛韦二丁酸酯前药的转运。HPβCD通过增溶疏水性前药并将其递送至角膜表面的粘蛋白层来改善角膜渗透。
J Ocul Pharmacol Ther. 2002-12
J Pharm Pharmacol. 2005-9
AAPS PharmSciTech. 2015-10
Pharmaceutics. 2021-3-19
AAPS PharmSciTech. 2015-10
World J Pharmacol. 2013
Ophthalmol Eye Dis. 2012-4-19
J Ocul Pharmacol Ther. 2002-12
Adv Drug Deliv Rev. 1999-3-1
J Control Release. 1999-5-1